A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
This study is an open label, randomized, multicenter study designed to compare the efficacy
of 12 weeks of subcutaneously administered efalizumab (monotherapy) with that of combination
therapy (Efalizumab and a topical corticosteroid ointment) in subjects with moderate to
severe plaque psoriasis who are candidates for systemic therapy. The study will also evaluate
the safety and tolerability of 30 months of continuous efalizumab treatment in those subjects
who derive benefit from the initial 12 weeks of treatment.